INTRODUCTION
Genetic alterations are key events in the evolution of many hematopoietic neoplasms in humans and mice. Most human leukemias are spontaneous however therapy-related radiation-induced myeloid-leukemias have been described. Radiation-induced leukemias in humans are predominantly myeloid and it was recognized early that radiation can induce both myeloid leukemias and lymphoid neoplasms in mice. 1, 2) The mechanism of radiation induced leukemogenesis in the mouse is a complex and multistep process, influenced by multiple genes. Chromosomal abnormalities appear to be involved in mouse radiation-induced hematopoietic malignancies. The specific chromosomal abnormalities are also found in many human hematopoietic neoplasms. Extensive strain differences in susceptibility to leukemias and lymphomas have been recognized early (reviewed by Murphy) 3) but their genetic basis still remains largely unknown.
To obtain information about the genetic architecture of radiation-induced hematopoietic neoplasms, we tested effects of whole body gamma irradiation in the CcS/Dem series of recombinant congenic (RC) strains. 4) The recombinant congenic CcS/Dem strains are specific genetic tools used to identify more than 50 loci controlling susceptibility to cancer and other complex diseases.
5) The twenty CcS RC strains were generated from a cross between the strain STS/A, which is resistant to radiation-induced tumors, and BALB/ cHeA, which is susceptible. 4, 6) Each CcS strain received a different, unique subset of about 12.5 percent of genes from the strain STS and the remaining genes from the strain BALB/c. 7, 8) As a result, the different genes of STS strain that influence susceptibility to radiation-induced hematopoietic neoplasms were separated into different CcS strains. We reported pre-viously that most CcS strains are relatively resistant, but some had high frequency (> 40%) of T-lymphomas. 9) Similarly, differences were observed in incidence of B-cell lymphomas and myeloid leukaemia. There was no correlation between strain susceptibilities to different tumors. In backcrosses between T-cell lymphoma resistant strain CcS-13 and the susceptible strain BALB/c we detected linkage of T-lymphoma susceptibility to BALB/c allele of D5Mit143 on the telomeric end of chromosome 9) and the resistant (STS) allele of D5Mit143 on chromosome 5 was frequently lost in a number of lymphomas. 10) Subsequently, linkage between a susceptibility locus for radiation lymphomagenesis and the marker D16Mit34 on mouse chromosome 16 was identified. 11) A new locus near D4Mit12 on chromosome 4 responsible for the susceptibility to the development of gammaradiation-induced thymic lymphoma was identified in experiments on BALB/c and MSM mice. 12) Allelic losses on chromosome 4 (Lyr2/TLSR5) were found to be associated with myeloid, B-lympho-myeloid and lymphoid (B and T) mouse radiation induced leukemias. 13) More recently two linked loci close to Cdkn2a on chromosome 4 were reported. 14) Analysis of the genetic determinism of the gammaradiation induced thymic lymphoma resistance in C57BL/6J and several inbred strains provided evidence for the existence of a thymic lymphoma resistance (Tlyr1) locus on chromosome 19. 15) In the present investigation we used backcross between strains CcS-17 and CcS-2 which differed with susceptibility to develop radiation-induced lymphoma and myeloid leukemia. CcS-17 had high incidence of T-cell lymphomas and low incidence of myeloid-granulocytic leukemias, whereas the opposite was found in CcS-2 mice. Here we describe the genetic determination of susceptibility to radiation-induced hematopoietic neoplasms in the backcross of the two CcS strains and characterize chromosomal abnormalities in obtained radiation-induced lymphomas and myeloidgranulocytic leukemias.
MATERIALS AND METHODS

Mice and tumor induction
Breeding pairs of recombinant congenic (RC) CcS/Dem strains were obtained from the breeding colony of P. Demant at the Netherlands Cancer Institute in Amsterdam. The CcS/Dem 305 backcross mice (CcS-17xCcS-2)xCcS-2, 141 males and 164 females, at the age of 35-42 days were exposed to whole-body irradiation. The mice were set at the concentric irradiation area (A = 625 cm 2 ) of γ-ray source 60 Co (Therathron 780E, Theratronix, Canada), at a distance 750 mm. Time of exposure was determined based on measured γ-ray distribution data from the source.
Four whole-body irradiation of doses of 1,7 Gy at one week intervals resulted in the total absorbed dose 6.8 Gy. Gamma-ray irradiation resulted in incidence of hematopoietic neoplasms that was sufficient for the statistical analysis.
Mice were housed in barrier system in SPF condition. They were bacteriologically, virologically, and parasitologically controlled. Animals were allowed ad libitum access to standard pelleted diet (LABOFEED H) and water. All animals were maintained in the animal facilities at the Cancer Center Institute of Oncology in Warsaw. Mice were examined weekly for signs of illness or malignancies. They were sacrificed when palpation revealed enlargement of the thymus, lymph nodes or/and spleen or when other clinical symptoms as poor grooming, hunched posture, cachexia were detected. Mice were sacrificed at the age of 700 days irrespective of signs of illness. The age of the mice at the date of sacrifice was recorded as their tumor age.
Tumor Pathology
Macroscopically visible tumors or suspected lesions were fixed in EAFS (ethanol, acetic acid, formol, 0.9% NaCl) and histologically examined after H&E staining. Immunophenotyping was performed using immunohistochemical ABComplex technique and by flow cytometry with the appropriate 12 monoclonal antibodies. 16) Immunohistochemical staining was performed on paraffin sections using antigen retrieval unmasking method -microwave oven heating and/or on airdried imprints. The neoplastic single-cell suspension (1 × 10 6 /1 ml) was analyzed by FACSCalibur Becton-Dickinson (San Jose, USA). The detailed procedure for FACS analysis was reported previously. 9, 17) The specific monoclonal antibodies (MAbs) for flow cytometry were labelled directly with FITC: CD90.2, CD3ε, CD8, CD45R-(B220), GAM (Goat anti Mouse Immunoglobulin) CD 79b, IA d or with PE: CD4, RAM KAPPA -(rat anti mouse κ); for immunohistochemistry MAbs were biotin conjugated: anti-IgM, CD45R-(B220), CD90.2, Gr-1 or pure anti-IgD. All antibodies were derived from BD PharMingen (San Jose, USA).
The histochemical staining-ASD method-assessment of chloroacetate esterase activity in immature granulocytes was done on each tumor. 18) Lymphoid and nonlymphoid hematopoietic neoplasms were classified according to the Bethesda proposals for classification of lymphoid neoplasms in mice 19) and the Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice, 20) which were produced by the Hematopathology Subcommittee of Mouse Models of Human Cancer Consortium.
Genotyping
Genomic DNA was isolated from tail tissues, the sample consisted of the whole tail 50 mm. Genomic Mini isolation kit (A&A Biotechnology Poland) was used according to manufacturer protocol for animal tissue.
21)
The PCR amplification was performed as described previously by Dietrich et al. 22) We used 24 microsatellite markers that covered the STS donor strain-derived regions that are located on segments of 14 chromosomes 7) and have different alleles in strains CcS-2 and CcS-17: D1Mit170, D1Mit207, D2Mit102, D2Mit51, D3Mit160, D3Mit162, D4Mit13, D5Mit179, D5Mit29, D6Mit59, D6Mit9, D7Mit57, D7Mit67, D9Mit85, D10Mit134, D10Mit12, D11Mit162, D12Mit46, D12Mit52, D15Mit22, D16Mit34, D16Mit5, D19Mit60, D19Mit61. The primers were purchased from SIGMA -Genosys (London, UK).
Statistical methods
Two types of lymphoma (T-and B-cell) and myeloidgranulocytic leukemia were analyzed separately for QTLs, with main effects and interactions by χ 2 test or by Fisher's exact test. Survival of mice was evaluated using KaplanMeier method.
P values were corrected for genome-wide significance either by conservative Bonferroni correction or by Lander and Kruglyak 23) method where the classification is based on the number of times that would be expected at random in a dense, complete genome scan. Four categories are proposed: -suggestive linkage (statistical evidence that would be expected one time in a genome scan), -significant linkage (statistical evidence expected 0.05 times in a genome scan -probability 5%), -highly significant linkage (statistical evidence expected 0.001 times in a genome scan), -and confirmed linkage when significant linkage is confirmed by independent investigators. Linkage was taken as suggestive in the backcross mice when P was less than 0.200.
Cytogenetic analysis and FISH study
Cells for cytogenetic analysis were obtained from neoplastic lymph node or/and thymus. Tissue specimens were mechanically fragmented and placed in cultured mediumEagle'a. Cell suspensions were incubated in cultured medium (Eagle'a) with colcemide for 1 hour. Chromosomes were prepared by the standard hypotonic KCl and methanol/acetic acid fixation procedure. G-bands were obtained with Wright stain. 24, 25) The karyotypes were described according to The International Committee on Standardized Genetic Nomenclature for Mice: Rules for Nomenclature of Chromosome Aberrations 26) and documented with Lucia imaging System. Aberrations were described according ISCN definition (ISCN2009) 27) as non-random in the particular case of neoplasm, if trisomies or structural aberrations repeated two times in the analyzed methaphases of hematopoietic cells harvested from the same case. Proliferation of hematopoietic cells was considered as clonal, neoplastic, when non-random aberrations were detected. 27) Aberrations found in G-banded chromosomes in metaphases were subsequently confirmed using FISH method with appropriate DNA probes Applied Spectral Imaging Ltd. (Migdal Ha'Emek, Israel). Hybridization signals were analyzed with Nikon Eclipse 850 fluorescence microscope (Nikon, Switzerland) and documented using LUCIA FISH imaging system (Laboratory Imaging, Czech Republic).
RESULTS
The lesions found in 305 (CcS-17xCcS-2)xCcS-2 mice are demonstrated in Table 1 .
We detected 139 hematopoietic neoplasms, in females 6 cases of lung tumors and 14 cases of ovarian tumors were associated with hematopoietic neoplasms.
Histopatological and immunological identification of hematopoietic neoplasms
129 cases were recognized as lymphoid neoplasms and 10 cases as nonlymphoid neoplasm. 116 lymphoid neoplasms were T-cell lymphomas and 13 cases were identified as B-cell lymphomas, 10 cases of nonlymphoid hematopoietic neoplasms were diagnosed as myeloid-granulocytic leukemia.
The T-cell lymphomas demonstrated lymphoblastic morphology and were diagnosed as Precursor T-cell lymphoblastic lymphoma Pre-T LBL. In immunohistochemical staining and in flow cytometry analysis, the lymphoid T neoplastic cells were always positive with CD90.2 and positive or negative with surface sCD3ε, CD4 and/or CD8.
Although, the lymphomas were histologically homogenous, they can be immunologically subdivided in six different immunophenotypes: I.
CD90 The incidence of T-cell lymphomas of individual immunophenotypes in males and females is represented in Table 2 . The myeloid-granulocytic leukemia was formed by immature granulocytes with bean or ring shaped nuclei. Mitotic figures were frequent. The neoplastic cells exhibited positive staining for chloroacetate esterase activity. Moreover, they were Gr-1 positive and CD90.2, sCD3ε, IgM, IgD, GAM, CD45R (B220) negative.
T-cell lymphomas exhibiting the I-VI immunophenotypes were used for the microsatellite analysis, while only the T-cell neoplasms, with immunophenotypes I and II, were selected for cytogenetic analysis, being the most representative samples. The selection was based on the following criteria:
T-cell lymphomas with immunophenotypes I and II showed the most frequent incidence, they differ with one surface sCD3ε antigen and are both derived from double positive T cells (CD4/CD8) + , the immature cortical thymocytes and only the T-cell lymphomas with immunophenotypes I or II in pilot cytogenic studies showed numerous chromosomal abnormalities. Finally, the 10 cases of T-cell lymphomas representing immunophenotype I CD90. 
Linkage of tumor susceptibility
Genomic DNA for microsatellite linkage analyses was obtained from 266 mice: 116 mice with developed T-cell lymphoma, 13 mice with B-cell lymphoma, 10 mice with myeloid-granulocytic leukemia and 127 mice without hematopoietic neoplasms. Genomic DNA from mice without any lesions were not analyzed. In reporting the linkage data we follow the recommendations of Lander and Kruglyak 23) that linkages with a suggestive genome-wide significance are reported, but the detected loci do not receive locus symbols. In fact, the levels of significance obtained here correspond to the levels reported in linkage studies of mouse radiation-induced tumors.
11) DNA of all mice with was genotyped for 24 microsatellite loci to map the genes responsible for radiation induced T-and B-cell lymphomas or myeloid-granulocytic leukemias. The data suggested a type-specific linkage of radiation induced hematopoietic neoplasms involving chromosome 10 (D10Mit134), 12 (D12Mit46), chromosome 5 (D5Mit179), and chromosome 16 (D16Mit34).
When testing each sex separately, linkage with D10Mit134 on chromosome 10 was identified at a suggestive level (χ 2 test, genome-wide significance P = 0.192). More females homozygous for STS allele at the D10Mit134 on chromosome 10 developed T lymphomas than the females carrying one BALB/c allele, but this was observed in the males in a lesser degree (see Table 3 ). It is therefore possible that the D10Mit134 on chromosome 10 is linked with T-cell lymphoma susceptibility in a sex dependent way; however, our data lack the power to demonstrate this sex dependence unequivocally. Two inter-locus interactions, one between D10Mit134 on chromosome 10 and D12Mit52 on chromosome 12 and the second between D10Mit134 on chromosome 10 and D12Mit46 on chromosome 12 were identified at a suggestive level of significance. Linkage between D10Mit134 on chromosome 10 and T-cell lymphoma susceptibility was confirmed when studied the group of mice heterozygous at D12Mit52 on chromosome 12 (genome-wide significance P = 0.104), or mice heterozygous at D12Mit46 on chromosome 12 (genome-wide significance P = 0.243) see Table 4 .
T-cell lymphoma survivals (Kaplan-Meier method) of mice either homozygous for STS allele or bearing one BALB/c allele at D10Mit134 on chromosome 10 were also found distinct in female mice (genome-wide P = 0.072) (Fig. 1) , mice heterozygous at D12Mit52 on chromosome 12 (genome-wide P = 0.144) (Fig. 2) and mice heterozygous at D12Mit46 on chromosome 12 (genome-wide P = 0.144) (Fig. 3) . T-cell lymphomas with immunophenotype I CD90.2 + sCD3ε -(CD4/CD8) + contribute to the linkage with D10Mit134 on chromosome 10 (data not shown).
A similar search was conducted subsequently for linkage of susceptibility to myeloid-granulocytic leukemia. No loci with main effect were discovered. When we tested two-way interactions in all non-linked pairs of markers, an interaction was found between D5Mit179 on chromosome 5 and D16Mit34 on chromosome16 at a suggestive level (Fisher exact test 3 d. f., genome-wide significance P = 0.154) see Table 5 .
Strain distribution patterns of 5 loci that are linked with S/S -STS homozygous genotype, S/C -STS and BALB/c heterozygous genotype, MG -mice with myeloid-granulocytic leukemia, NMG -mice without myeloid-granulocytic leukemia (mice without any neoplasms or mice with other neoplasms than myeloid-granulocytic leukemia) susceptibility to hematopoietic neoplasms typed in CcS-2 and CcS-17 strains, respectively, are: D10Mit134, S, C; D12Mit52, S, C; D12Mit46, S, C; D5Mit179, S, C; D16Mit34, S, C.
Cytogenetic analysis
We detected non-random numerical and structural chro- (Fig. 4A) . The trisomy Ts (14) was seen once in the case T-03, additionally to the structural aberration which involved chromosome X. The additional, derivative chromosome X copy was manifested as the translocation T(X;?). In the case T-04 the structural aberration, translocation T(X;9) was noticed (data not shown). Among B-cell lymphomas we found structural aberrations that involved chromosome 2 (two cases) and 12 (one case). The material of chromosome 2 was involved in non-reciprocal translocation with chromosome 12 T(2;12) -the case B-01 (Fig. 4B) . The break point on chromosome 2 was in band E5-F1 and the breakpoint on chromosome 12 was in the region of Igh locus, on the distal part of the chromosome. In the case B-02 the amplification of material from chromosome 2 was observed as a derivative chromosome 2 copy involved in translocation with an undefined chromosome (data not shown). In metaphases of 4 hyperdiploid cases (41-42 chr/cell) supernumerary, unidentifiable markers were observed.
In three cases of myeloid-granulocytic leukemia the majority (~80%) of analyzed metaphases showed polyploid pattern of chromosomes (modal chromosomal number 80 chr/cell). The abnormal karyotypes obtained by G-banding and FISH are shown in Table 6 .
DISCUSSION
The study linkage analysis revealed a tentative locus for susceptibility to radiation induced lymphomagenesis at the marker D10Mit134 on chromosome 10. That association was found with radiation induced T-cell lymphomas. This locus may affect susceptibility to radiation induced T-cell lymphomas in a sex-dependent way, as the linkage is suggestive in females but not in males. More female mice homozygous for the allele D10Mit134 on chromosome 10 derived from the resistant strain STS (inherited from CcS-2 -genotype SS) are susceptible to leukemogenesis than the females with one allele derived from the susceptible strain BALB/c (inherited from CcS-17 -genotype CS). This apparently paradoxical result likely indicates that the resistance of the strain STS is caused by multiple genes, but they are not linked to D10Mit134 on chromosome 10.
The region of chromosome 10 close to D10Mit134 contains several genes that were associated in tumorigenesis and leukemogenesis. Deregulation of the expression of Dcn (55.0cM) 28) and Glipr1 29) located in the vicinity of D10Mit134 (59.0cM) on chromosome 10 may lead to increased risk of T-cell lymphoma. The alteration in Dcn gene results in development of T-cell lymphoma and a mutation in Glipr1 gene decreases apoptosis and hence it may cause the increase of the incidence of lymphoma. The marker D10Mit134 (59.0cM) on chromosome 10 is also located in the vicinity of Kitl (57.0cM), Mdm2 (66.0cM) and Ifng (67.0cM). Mutants of Kitl show mild to severe defects in hematopoiesis. 30) Kitl is essential for the development of hematopoietic cells as well as germ cells, and melanocytes. 31) Mdm2 and Ifng can be involved in tumorigenesis, but they are largely involved in developing B-cell lymphoma. Overexpression of Mdm2 plays crucial role both in p53-dependent and p-53 independent tumorigenesis. 32) Mdm2+/-Mdm4+/-double-heterozygous mice exhibit defects in hematopoiesis. 33) Deficiency in production of interferon gamma (encoded by Ifng) promotes development of diverse hematologic neoplasms on the background of persistent inflammation because activated B cells show resistance to apoptosis. 34) Low production of IFNγ is associated with increased infiltration of lymphocytes into tumors, where they may support inflammation and indirectly stimulate growth and progression. 35) The literature provides more data indicating that the genomic region close to the marker D10Mit134 on chromosome 10 is involved in leukemogenesis. The DNA copy number partial gains of chromosome 10 (band C1) were observed in thymic lymphomas from C3H mice 36) and in MNU-induced lymphomas.
37) The present paper links for the first time this chromosomal region to susceptibility to radiation-induced lymphomas.
We observed a linkage of marker D16Mit34 on chromosome 16 with myeloid-granulocytic leukemias but we did not detect an association of markers D16Mit5 on chromosome 16 and D16Mit34 on chromosome 16 with susceptibility to lymphomagenesis. We merely observed chromosomal abnormalities involving chromosome 16 in two cases of T-cell lymphomas with the chromosomal marker Rb (16.16) .
The results, however, show that is necessary to look for regions on chromosome 16 important for the development of T-cell lymphoma.
A susceptibility locus for radiation lymphomagenesis on mouse chromosome 16 was detected in CcS/Dem recombinant congenic strains and in other inbred strains. 11, 38) The strain-associated genomic imbalances on chromosomes 16 and 10 in thymic lymphomas from C3H mice and numerous copy number aberrations on chromosome 16 in thymic lymphomas were reported. 36) Tlsr7 locus on chromosome16 was found to undergo allelic loss at high frequency in mouse thymic lymphoma. 39) At least two genes-Prkdc (cM 9.2) and Crebbp and the QTL Ritls on mouse chromosome 16 are involved in lymphomagenesis in mice. Prkdc was suggested as a candidate for radiation induced apoptosis 1 (Rapop1) and for gene controlling susceptibility to radiation lymphomagenesis. 40) Prkdc ablation is associated with markedly higher incidence of T-cell lymphomas in DNA-PKcs-defective mice (DNA- 41) Crebbp is involved in hemopoiesis. 42, 43) Ritls is associated with susceptibility to leukemia induced by radiation-induced leukemia virus (RadLV) obtained from a radiation-induced leukemia. 11, 44) The data presented here point to a likely interaction of genes on chromosomes 5 and 16 and their involvement in susceptibility to myeloid-granulocytic leukemia. More mice heterozygous at D16Mit34 on chromosome 16 and at D5Mit179 on chromosome 5 develop myeloid-granulocytic leukemia than mice homozygous for STS at the two loci. It may suggest that BALB/c alleles at the loci confer sensitivity to myeloid-granulocytic leukemia though these alleles were inherited from CcS-17 strain with low incidence of myeloid-granulocytic leukemia. Two genes in vicinity of D5Mit179 on chromosome 5 may be involved in susceptibility to leukemogenesis: Dmtf1 and Rint 1 (RAD-50 interacting protein). Human ortholog of Dmtf1 hDMP1 gene is located on Chr. 7 the locus of which is often deleted in myeloid leukemia. 45 ) Rint 1 is a tumor suppressor gene.
46)
The data from literature indicates aberrations on chromosome 2 associated with ALM-acute myeloid leukemia in mice. [47] [48] [49] Specific delations that involved regions D-E on one copy of chromosome 2 were reported as associated with radiation induced myeloid leukemias. [50] [51] [52] [53] [54] In addition, higher proliferative potential was demonstrated with regards to chromosome 2 aberrant clones from bone marrow cells. 55) Loss of a region of chromosome 2 containing the PU.1 gene (50.44cM)-cytoband E3 was detected in radiation leukemogenesis. 56) PU.1 gene is a candidate as myeloid leukemic tumor suppressor gene. 57) Translocations of chromosome 2 (D-E) were observed in radiation-induced acute leukemias in CBA/Ca mice. 58) However, in our study, chromosome 2 was involved in a translocation in B-cell lymphoma but not in myeloid leukemia.
In contrast to the data from literature we found no significant chromosomal aberrations in myeloid-granulocytic leukemia. Presumably, clonal selection resulted in proliferation of neoplastic cells with alterations on chromosomes 5 and 16. The alterations were not visible at the level of cytogenetic detection. Furthermore, the genetic architecture of radiation-induced AMLs which result from mutations in a single hematopoietic stem cell may vary from the observed myeloid-granulocytic leukemias, that derivate from a mutated hematopoietic cell at further stages of differentiation.
We found in the analyzed B-cell lymphomas two instances of the involvement of chromosome 2 with the break point in band E5-F1. One of these tumors exhibits also a simultaneous involvement of chromosome 12 with the breakpoint in the region of Igh locus, on the distal part of the chromosome. We assume that the aberration should be considered for possible correlation with the process of mice lymphomagenesis.
The literature contains data that indicates a presence of chromosomal aberrations with involvement of Chr12 in mouse lymphomas. The involvement of locus Igh on chromosome 12 in mouse lymphomas was reported. [59] [60] [61] The Igh gene was involved in some cases of pro-B-cell lymphomas with translocation T(12;15). 62) Chromosome translocations involving the IgH locus with one of several cellular proto-oncogenes, leading to deregulated oncogene expression are crucial points in the pathogenesis of B-cell lymphoid malignancies in humans. [63] [64] [65] The loci involved in susceptibility to lymphomagenesis may have analogies to genomic alterations associated with lymphomas and leukemias in human. The genomic region in vicinity of the marker D10Mit134 (59.0cM) on mouse chromosome 10, associated with susceptibility to T-cell lymphoma, is homologous to the regions on human chromosome 12q14 and 12q22. Overexpression of the gene MDM2 (mouse ortholog Mdm2) located in the region 12q14.3-q15 is observed in some types of human B-cell lymphomas/leukemias and myeloid leukemias. 66, 67) The region of mouse chromosome 5 in vicinity of the marker D5Mit179 (8.0cM) involved in myeloid-granulocytic leukemia, was mapped on human Chr7q11 as well as Chr7q36. The translocation t(7;12)(q36;p13) was detected in some acute myeloid leukemia and acute lymphoblastic leukemia. [68] [69] [70] The region in vicinity of the marker D16Mit34 (9.61cM) on chromosome 16 is mapped on human chromosomes 8q11 and 22q11. The human gene SEPT5 (hCDRel-1, human cell division cycle regulation) located on 22q11 was shown in translocation t(11;22)(q23;q11.2) in individual cases of human ALM with maturation. 71) An involvement of 8q11 and 22q11 in human T-cell lymphomas are rare. 72) More frequent rearrangements of chromosomal bands 8q11 and 22q11 are visible in human B-cell lymphomas. [73] [74] [75] The genes located in the regions where association with leukemogenesis was found, see in Table 7 .
The present results of linkage analysis may be revealing an emerging trend of fusion of the sets of genes and genetic region involved in hematopoietic tumors. Our data may also provide additional information for the study of mechanisms of therapy-induced leukemogenesis after exposure to radiation. These investigations can also be useful for better modeling of the disease and will consequently lead to a tailored treatment of hematopoietic neoplasms in humans.
